All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit the MDS Alliance.
The MDS Hub uses cookies on this website. They help us give you the best online experience. By continuing to use our website without changing your cookie settings, you agree to our use of cookies in accordance with our updated Cookie Policy
Introducing
Now you can personalise
your MDS Hub experience!
Bookmark content to read later
Select your specific areas of interest
View content recommended for you
Find out moreThe MDS Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the MDS Hub cannot guarantee the accuracy of translated content. The MDS Hub and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.
Phase III Dacota trial: Will hydroxyurea remain SoC for advanced proliferative CMML?
Bookmark this article
During the 62nd American Society of Hematology (ASH) Annual Meeting and Exposition, the MDS Hub spoke to Raphael Itzykson, Université de Paris, Paris, FR, about the phase III Dacota trial. We asked, Will hydroxyurea remain standard of care for advanced proliferative chronic myelomonocytic leukemia (CMML)?
Phase III Dacota trial: Will hydroxyurea remain SoC for advanced proliferative CMML?
Itzykson discusses the results from the randomized phase III Dacota trial evaluating decitabine versus hydroxyurea in patients with advanced proliferative CMML.
More about...
Related articles
Newsletter
Subscribe to get the best content related to MDS delivered to your inbox